Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare’s Sativex begins cancer pain trial

Bayer HealthCare’s Sativex begins cancer pain trial

24th November 2010

Bayer HealthCare's drug Sativex has commenced a phase III clinical trial programme to gauge its potential as a therapy for pain among advanced cancer patients.

The evaluation programme will consist of two multinational placebo-controlled trials, with each study assessing the efficacy of the drug among 370 patients over a five-week period.

Sativex is currently approved in Europe as a therapy for spasticity among multiple sclerosis patients and has been developed by GW Pharmaceuticals.

Bayer HealthCare holds the UK marketing rights to the treatment, with US and European distribution handled by Otsuka Pharmaceutical and Almirall respectively.

The first phase III trial site for the treatment has now been initiated in Europe, with recruitment expected to begin in December 2010, while the second study will commence in mid-2011.

Earlier this week, Bayer HealthCare published clinical data from two phase III trials of the age-related macular degeneration treatment VEGF Trap-Eye, demonstrating the drug's efficacy compared to the current standard of care.ADNFCR-8000103-ID-800253385-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.